 Joshua Klopper
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 19 | 2026 | 370 | 2.050 |
Why?
| | Tetrahydronaphthalenes | 3 | 2015 | 34 | 0.770 |
Why?
| | Thyroid Nodule | 5 | 2026 | 62 | 0.660 |
Why?
| | Carcinoma, Papillary | 5 | 2015 | 82 | 0.620 |
Why?
| | Thiazolidinediones | 4 | 2013 | 143 | 0.610 |
Why?
| | Retinoids | 3 | 2009 | 36 | 0.550 |
Why?
| | Adenocarcinoma, Follicular | 2 | 2015 | 43 | 0.450 |
Why?
| | Retinoid X Receptors | 4 | 2010 | 42 | 0.430 |
Why?
| | Anticarcinogenic Agents | 1 | 2015 | 63 | 0.420 |
Why?
| | PPAR gamma | 4 | 2013 | 182 | 0.400 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 19 | 0.330 |
Why?
| | Triiodothyronine | 1 | 2011 | 55 | 0.330 |
Why?
| | Carcinoma | 2 | 2015 | 227 | 0.330 |
Why?
| | Thyroxine | 1 | 2011 | 67 | 0.330 |
Why?
| | Hypothyroidism | 1 | 2011 | 68 | 0.320 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 56 | 0.320 |
Why?
| | Calcitriol | 1 | 2010 | 58 | 0.310 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 209 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 1969 | 0.220 |
Why?
| | Retinoid X Receptor gamma | 1 | 2004 | 5 | 0.210 |
Why?
| | Biomarkers, Tumor | 2 | 2026 | 1329 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2026 | 457 | 0.190 |
Why?
| | Melanoma | 2 | 2009 | 762 | 0.190 |
Why?
| | Gene Expression Profiling | 4 | 2023 | 1777 | 0.190 |
Why?
| | Liver | 1 | 2011 | 1899 | 0.180 |
Why?
| | Carrier Proteins | 1 | 2026 | 729 | 0.180 |
Why?
| | Cell Line, Tumor | 6 | 2010 | 3551 | 0.170 |
Why?
| | Promoter Regions, Genetic | 1 | 2026 | 1247 | 0.170 |
Why?
| | Biopsy, Fine-Needle | 6 | 2023 | 74 | 0.160 |
Why?
| | Decision Support Techniques | 2 | 2015 | 480 | 0.160 |
Why?
| | Antineoplastic Agents | 3 | 2008 | 2219 | 0.150 |
Why?
| | Mutation | 2 | 2026 | 4090 | 0.140 |
Why?
| | Thyroidectomy | 2 | 2015 | 94 | 0.130 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2012 | 411 | 0.130 |
Why?
| | Hypocalcemia | 1 | 2015 | 40 | 0.110 |
Why?
| | Lymph Nodes | 2 | 2015 | 509 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2009 | 936 | 0.110 |
Why?
| | Ligands | 2 | 2009 | 668 | 0.110 |
Why?
| | Interinstitutional Relations | 1 | 2014 | 56 | 0.100 |
Why?
| | Receptors, Retinoic Acid | 2 | 2004 | 44 | 0.100 |
Why?
| | Access to Information | 1 | 2014 | 48 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 883 | 0.100 |
Why?
| | Medical Record Linkage | 1 | 2014 | 69 | 0.100 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 201 | 0.100 |
Why?
| | Humans | 25 | 2026 | 145783 | 0.090 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 273 | 0.090 |
Why?
| | Lymphatic Metastasis | 4 | 2015 | 336 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2016 | 587 | 0.090 |
Why?
| | Ultrasonography | 1 | 2015 | 788 | 0.080 |
Why?
| | Benzoates | 2 | 2009 | 51 | 0.080 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 14 | 0.080 |
Why?
| | Cell Proliferation | 3 | 2009 | 2514 | 0.080 |
Why?
| | Steroid Hydroxylases | 1 | 2010 | 20 | 0.080 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2010 | 17 | 0.080 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 19 | 0.080 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2012 | 266 | 0.080 |
Why?
| | Paclitaxel | 2 | 2013 | 259 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1191 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2010 | 209 | 0.070 |
Why?
| | Databases, Factual | 1 | 2015 | 1491 | 0.070 |
Why?
| | Patient Care Team | 1 | 2014 | 697 | 0.070 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2009 | 104 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 160 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1582 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 410 | 0.070 |
Why?
| | Middle Aged | 8 | 2026 | 36309 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 615 | 0.070 |
Why?
| | Iodine Radioisotopes | 1 | 1988 | 138 | 0.060 |
Why?
| | Cell Survival | 1 | 2010 | 1104 | 0.060 |
Why?
| | Transcriptome | 1 | 2013 | 1042 | 0.060 |
Why?
| | Female | 12 | 2026 | 79045 | 0.060 |
Why?
| | Vitamin D | 1 | 2010 | 404 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2171 | 0.060 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 638 | 0.060 |
Why?
| | Mice, Nude | 1 | 2008 | 680 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2014 | 1202 | 0.060 |
Why?
| | Prognosis | 3 | 2026 | 4330 | 0.060 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 106 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 751 | 0.060 |
Why?
| | Registries | 1 | 2015 | 2410 | 0.060 |
Why?
| | Milk, Human | 1 | 1988 | 175 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 375 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 979 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 442 | 0.060 |
Why?
| | Luciferases | 1 | 2004 | 154 | 0.050 |
Why?
| | Immunoprecipitation | 1 | 2004 | 149 | 0.050 |
Why?
| | Aged | 4 | 2026 | 26217 | 0.050 |
Why?
| | Male | 9 | 2026 | 73011 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2015 | 11794 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2015 | 2977 | 0.050 |
Why?
| | Mice | 3 | 2009 | 18356 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 1184 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2181 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2023 | 17330 | 0.040 |
Why?
| | Adult | 5 | 2026 | 40881 | 0.040 |
Why?
| | Neoplasm Invasiveness | 2 | 2012 | 508 | 0.040 |
Why?
| | Gene Expression | 1 | 2004 | 1478 | 0.040 |
Why?
| | Apoptosis | 2 | 2004 | 2444 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2014 | 1475 | 0.030 |
Why?
| | Genomics | 1 | 2023 | 830 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 2000 | 0.030 |
Why?
| | Animals | 3 | 2009 | 38102 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 1512 | 0.030 |
Why?
| | Thyroid Gland | 2 | 2010 | 91 | 0.030 |
Why?
| | Transcription Factors | 1 | 2004 | 1736 | 0.030 |
Why?
| | Neck | 1 | 2015 | 109 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2015 | 70 | 0.030 |
Why?
| | National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2014 | 1 | 0.030 |
Why?
| | Perioperative Period | 1 | 2014 | 71 | 0.030 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2013 | 15 | 0.030 |
Why?
| | Expert Testimony | 1 | 2014 | 43 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 618 | 0.020 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2013 | 37 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2014 | 268 | 0.020 |
Why?
| | Research | 1 | 2015 | 431 | 0.020 |
Why?
| | Adiponectin | 1 | 2013 | 242 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 463 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 637 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2012 | 322 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1139 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2010 | 78 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2010 | 179 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 461 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1898 | 0.020 |
Why?
| | Internet | 1 | 2014 | 693 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 693 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1662 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 8347 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1723 | 0.020 |
Why?
| | Patient Participation | 1 | 2012 | 446 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2008 | 2805 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1165 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1133 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2934 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3634 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2010 | 420 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1450 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2014 | 948 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2014 | 2050 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Chromans | 1 | 2006 | 25 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2008 | 258 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1988 | 289 | 0.010 |
Why?
| | Risk Assessment | 1 | 2015 | 3752 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 1150 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2009 | 1115 | 0.010 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 239 | 0.010 |
Why?
| | Breast Feeding | 1 | 1988 | 447 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1146 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 8078 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2004 | 399 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 757 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 887 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6033 | 0.010 |
Why?
| | Algorithms | 1 | 2009 | 1851 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 598 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3418 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2009 | 5428 | 0.010 |
Why?
| | United States | 1 | 2014 | 16126 | 0.010 |
Why?
| | Young Adult | 1 | 2010 | 14254 | 0.010 |
Why?
|
|
Klopper's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|